Addressing the Risks of Respiratory Syncytial Virus for Patients With Inflammatory Bowel Disease in the Era of Novel Vaccines

Inflamm Bowel Dis. 2023 Nov 2;29(11):1842-1845. doi: 10.1093/ibd/izad233.

Authors

Ryan A Smith¹, Aakash Desai², Jana G Hashash², Mary S Hayney³, Francis A Farraye², Freddy Caldera¹

Affiliations

¹ Division of Gastroenterology and WI, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
² Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
³ School of Pharmacy, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.

PMID: 37816231
DOI: 10.1093/ibd/izad233

No abstract available

MeSH terms

Antibodies, Viral
Humans
Inflammatory Bowel Diseases*
Respiratory Syncytial Virus Infections* / prevention & control
Respiratory Syncytial Virus, Human*
Vaccination
Vaccines*

Substances

Vaccines
Antibodies, Viral